Join our daily newsletter At The Bell to receive exclusive market insights
- Medlab Clinical (MDC) receives human ethics approval for Australian sites for its non-opioid pain medication, NanaBis
- The approval is for a phase three cancer bone pain trial, which aims to be rolled out across Australia, the U.S. and the U.K.
- Last year, NanaBis met all the primary and secondary endpoints for a clinical trial
- On the market this afternoon, Medlab was up 3.13 per cent, trading at 16.5 cents per share
Medlab Clinical (MDC) have received human ethics approval for Australian sites for its NanaBis cancer bone pain phase three trial.
A well-known Australian Human Research Ethics Committee (HREC), Belberry, has granted approvals for two sites — Professor Stephen Clarke at GenesisCare in Sydney and Professor Phil Good at the Mater Hospital in Brisbane.
Notably, Professor Clarke was the private investigator in the March 2020 trials.
NanaBis is the company’s most advanced non-opioid pain medication using its NonoCelle platform.
The drug is gearing up for a global phase three trial involving Australia, the United Kingdom and the United States.
Last year, NanaBis met all the primary and secondary endpoints for a clinical trial, which included improvements in pain, increases in quality of life and opioid-sparing.
Medlab’s regulatory strategy is to meet the US Food and Drug Administration for cancer bone pain by 2024 and then undertake a marketing claims expansion trial
to seek secondary claims approval for cancer pain.
Now, the company is reviewing two other Australian Sites that may be included in this HREC approval.
On the market this afternoon, Medlab was up 3.13 per cent, trading at 16.5 cents per share at 1:25 pm AEST.
